Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

These stocks are all trading near their 52-week lows, and could be attractive options to consider. They all possess promising ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...

President-elect Donald Trump has asserted that, due to national security interests, he intends to acquire Greenland and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

ORG Partners LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 181.7% in the fourth quarter, ...

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $86.26 which represents a slight increase of $0.62 or 0.72% from the prior close of $85.64. The stock opened at $87.22 and touched a ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...